Description: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Home Page: amicusrx.com
47 Hulfish Street
Princeton,
NJ
08542
United States
Phone:
609 662 2000
Officers
| Name | Title |
|---|---|
| Mr. Bradley L. Campbell M.B.A. | CEO, President & Director |
| Mr. Simon Nicolas Reade Harford | Chief Financial Officer |
| Ms. Ellen S. Rosenberg J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. David M. Clark | Chief People Officer |
| Dr. Jeffrey P. Castelli Ph.D. | Chief Development Officer |
| Ms. Samantha Prout | Chief Accounting Officer & Controller |
| Dr. Jill Weimer Ph.D. | Chief Science Officer |
| Mr. Andrew Faughnan | Senior Director of Investor Relations |
| Mr. Patrik S. Florencio Esq. | Global Chief Compliance & Risk Officer |
| Ms. Diana Moore | Head of Global Corporate Communications |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 32.4675 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 16.184 |
| Price-to-Sales TTM: | 5.6197 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 500 |